prednisolone has been researched along with Hip Fractures in 5 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Hip Fractures: Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "34 years), there were 27 hip fractures in the alendronate group and 73 in the no-alendronate group, corresponding to incidence rates of 9." | 3.85 | Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. ( Axelsson, KF; Lorentzon, M; Lundh, D; Nilsson, AG; Wedel, H, 2017) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axelsson, KF | 1 |
| Nilsson, AG | 1 |
| Wedel, H | 1 |
| Lundh, D | 1 |
| Lorentzon, M | 1 |
| Nagano, S | 1 |
| Mori, M | 1 |
| Kato, A | 1 |
| Ono, Y | 1 |
| Aoki, K | 1 |
| Arima, H | 1 |
| Takiuchi, Y | 1 |
| Tabata, S | 1 |
| Yanagita, S | 1 |
| Matsushita, A | 1 |
| Ishikawa, T | 1 |
| Imai, H | 1 |
| Takahashi, T | 1 |
| Miyanishi, K | 1 |
| Hara, T | 1 |
| Hamada, T | 1 |
| Maekawa, M | 1 |
| Tsurusaki, S | 1 |
| Moro-oka, TA | 1 |
| Kamo, Y | 1 |
| Jingushi, S | 1 |
| Torisu, T | 1 |
| Tateiwa, T | 1 |
| Shinmura, K | 1 |
| Ko, M | 1 |
| Mibe, J | 1 |
| Yamamoto, K | 1 |
| Lian, KC | 1 |
| Lang, TF | 1 |
| Keyak, JH | 1 |
| Modin, GW | 1 |
| Rehman, Q | 1 |
| Do, L | 1 |
| Lane, NE | 1 |
5 other studies available for prednisolone and Hip Fractures
| Article | Year |
|---|---|
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female | 2017 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Co-occurrence of subchondral insufficiency fracture of the femoral head and contralateral femoral neck fracture in a rheumatic patient receiving steroid treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diagnosis, Differential; Drug | 2008 |
Iliopectineal bursitis associated with rapid destruction of a rheumatoid hip joint.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement | 2009 |
Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women.
Topics: Absorptiometry, Photon; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone Diseases, Metabolic | 2005 |